Abstract 2120P
Background
Malnutrition is frequent, but underdiagnosed consequence of gastrectomy. Nutritional status is an important factor influencing optimal recovery after treatment. The aim of the present study was to assess the prevalence of micronutrient deficiencies post gastrectomies.
Methods
Between January 2022 and January 2023, 115 patients post gastrectomy had micronutrient screening including vitamin B12, vitamin D, folate, ferritin and albumin. Patients with any micronutrients deficiency were invited for a follow-up and rehabilitation (nutrient rich diet, supplements). Descriptive statistics and t-tests.
Results
Patients’ characteristics were as follow: 64.3% women and 35.6% men; median age 58 [30-81]; median follow-up period 19 months [2-24]; proportion of patients with deficiency in vitamin B12, vitamin D, folate, ferritin and albumin were 5.2%,40%,10.4%, 23.4% and 20.9%, respectively. We observed significant improvement in several indicators (vitamin B12 156→357mmol/l, vitamin D 24.6→69.4mmol/l, folate 2.7→9.6mmol/l, ferritin 16.4→92.2mmol/l, albumin 2.2→3.0mmol/l, p=0.01).
Conclusions
This study defined the prevalence of micronutrient deficiencies post gastrectomy. Appropriate nutritional intervention based on findings micronutrients deficiency led to improve quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06